Key result
Lomitapide is an effective treatment option for lowering LDL-C in patients with homozygous familial hypercholesterolemia who are refractory to LDLR-dependent therapies.
Why the study?
Achieving recommended LDL-C targets in homozygous familial hypercholesterolemia is challenging and necessitates combination therapy, prompting a review of the available long-term evidence for lomitapide.
Does lomitapide reduce LDL-C in patients with homozygous familial hypercholesterolemia?
Does lomitapide reduce LDL-C in patients with homozygous familial hypercholesterolemia?
Lomitapide provides an effective LDL-C lowering option for HoFH patients refractory to standard LDLR-dependent therapies.
May support lomitapide in refractory HoFH; leaves open need for randomized confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Arca et al. (2025) conducted a review in Homozygous familial hypercholesterolemia (HoFH). Lomitapide was evaluated. Lomitapide is an effective treatment option for lowering LDL-C in patients with homozygous familial hypercholesterolemia who are refractory to LDLR-dependent therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: